We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Lucknow Model College of Pharmacy, Lucknow
Hypertension is one of the most common cardiovascular disorders and a major cause of morbidity and mortality worldwide. Losartan potassium, a selective angiotensin II receptor blocker (ARB), is extensively prescribed for the treatment of hypertension, diabetic nephropathy, and cardiovascular complications. However, oral administration of losartan potassium is associated with poor bioavailability due to extensive hepatic first-pass metabolism and variable gastrointestinal absorption. These limitations have encouraged the development of alternative drug delivery systems capable of enhancing therapeutic efficacy and patient compliance. Transdermal drug delivery systems (TDDS) have emerged as a promising alternative because they bypass first-pass metabolism, maintain controlled plasma drug concentrations, reduce dosing frequency, and improve patient adherence. Nevertheless, the stratum corneum presents a significant barrier to drug penetration through the skin. Nanotechnology-based approaches have been investigated extensively to overcome these challenges. Nano-embedded transdermal systems incorporating polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and liposomes have demonstrated improved skin permeation, enhanced bioavailability, controlled drug release, and increased therapeutic effectiveness. The present review provides a comprehensive overview of the design, optimization, and characterization of nano-embedded losartan potassium transdermal therapeutic systems. The formulation strategies, nanocarrier selection, optimization methodologies, evaluation techniques, recent developments, and future perspectives are critically discussed. The integration of nanotechnology with transdermal drug delivery offers significant opportunities for improving antihypertensive therapy and represents a promising area of pharmaceutical research.
Hypertension is a chronic cardiovascular disorder characterized by persistently elevated arterial blood pressure. According to global health reports, hypertension affects more than one billion people worldwide and remains one of the leading causes of cardiovascular disease, stroke, kidney failure, and premature death. Effective management of hypertension is therefore essential to reduce disease burden and improve patient outcomes. Among the available antihypertensive agents, losartan potassium has gained considerable importance due to its efficacy, safety profile, and ability to selectively block angiotensin II type-1 receptors. Angiotensin II is a potent vasoconstrictor responsible for increased blood pressure, sodium retention, and cardiovascular remodeling. By inhibiting the action of angiotensin II, losartan effectively lowers blood pressure and protects against cardiovascular complications. Despite its clinical usefulness, losartan potassium exhibits several pharmacokinetic limitations when administered orally. The drug undergoes extensive first-pass metabolism in the liver, resulting in reduced systemic bioavailability. Furthermore, fluctuations in plasma drug concentrations may occur due to variable absorption and frequent dosing requirements. These challenges have motivated researchers to investigate alternative drug delivery approaches capable of enhancing therapeutic performance. Transdermal drug delivery systems have emerged as a valuable strategy for improving drug administration. Unlike oral dosage forms, transdermal systems deliver drugs directly through the skin into systemic circulation. This route offers several advantages, including avoidance of gastrointestinal degradation, elimination of hepatic first-pass metabolism, sustained drug release, improved patient compliance, and reduced side effects.
Transdermal Drug Delivery Systems
Transdermal drug delivery refers to the administration of therapeutic agents through intact skin for systemic absorption. The concept was developed to overcome the limitations associated with conventional oral and injectable dosage forms.
A typical transdermal therapeutic system consists of:
The drug is released from the formulation and diffuses through the skin layers before entering systemic circulation.
Losartan Potassium: Pharmaceutical Profile
Chemical Name
Potassium 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl) benzyl] imidazole-5- methanol.
Molecular Formula
C22H22ClKN6O
Molecular Weight
l Approximately 461 g/mo
Category
Angiotensin II Receptor Blocker (ARB)
Mechanism of Action
Losartan selectively blocks angiotensin II type-1 receptors, preventing vasoconstriction and reducing blood pressure.
Indications
Rationale for Nano-Embedded Losartan Potassium TDDS
The incorporation of nanotechnology into transdermal systems provides numerous advantages:
Enhanced Skin Permeation
Nano-sized carriers can penetrate skin barriers more effectively.
Improved Drug Solubility
Nanocarriers increase the apparent solubility of poorly soluble drugs.
Controlled Drug Release
Drug release profiles can be tailored according to therapeutic requirements.
Enhanced Stability
Nanoparticles protect drug molecules from degradation.
Improved Bioavailability
Avoidance of first-pass metabolism improves systemic drug exposure.
Reduced Dosing Frequency
Sustained release systems maintain therapeutic concentrations for extended periods.
Nanocarriers Used In Losartan Potassium Transdermal Therapeutic Systems
Nanocarriers are submicron-sized delivery systems designed to improve drug solubility, stability, bioavailability, and therapeutic performance. Various nanocarriers have been investigated for the transdermal delivery of losartan potassium.
Polymeric Nanoparticles
Polymeric nanoparticles are colloidal carriers prepared using biodegradable and biocompatible polymers. These systems can entrap drugs within polymer matrices or adsorb them onto their surfaces.
Commonly Used Polymers
Advantages
Disadvantages
Polymeric nanoparticles have shown significant potential in achieving prolonged antihypertensive activity through controlled transdermal delivery.
Solid Lipid Nanoparticles (SLNs)
Solid lipid nanoparticles are composed of physiological lipids that remain solid at both room and body temperature.
Components
Common Lipids
Advantages
Limitations
SLNs are widely explored because their lipid composition closely resembles skin lipids, facilitating permeation through the stratum corneum.
Nanostructured Lipid Carriers (NLCs)
Nanostructured lipid carriers represent the second generation of lipid-based nanoparticles.
NLCs consist of:
The presence of liquid lipids creates imperfections within the crystal lattice, allowing higher drug loading.
Advantages
Importance in Losartan Delivery
Several studies have demonstrated that NLC-based transdermal systems significantly improve losartan permeation and prolong antihypertensive activity.
Nanoemulsions
Nanoemulsions are kinetically stable dispersions with droplet sizes generally ranging from 20–200 nm.
Types
Components
Advantages
Mechanism of Enhanced Permeation
Nanoemulsions fluidize skin lipids and increase drug partitioning into the stratum corneum, thereby enhancing penetration.
Comparison of Nanocarriers Used for Losartan Potassium TDDS
Table: 1 Comparison Of Nanocarriers Used For Losartan Potassium TDDS
|
Nanocarrier |
Advantages |
|
polymeric Nanoparticles |
Controlled release, stability |
|
SLNs |
Biocompatibility, skin penetration |
|
NLCs |
High loading, better stability |
|
Nanoemulsions |
High permeation, easy preparation |
|
Liposomes |
Biocompatibility, hydration High production cost |
Formulation Design Of Nano-Embedded Losartan Potassium Patches
The design of a successful transdermal system depends on the careful selection of formulation components and manufacturing parameters.
Drug Selection
An ideal candidate for transdermal delivery should possess:
Losartan potassium satisfies many of these requirements and can be further optimized through nanocarrier incorporation.
Polymer Selection
Polymers form the matrix of the transdermal patch.
Common Polymers
Hydrophilic Polymers
Hydrophobic Polymers
Desired Characteristics
Optimization of Nano-Embedded Losartan Potassium Systems
Optimization is critical for obtaining formulations with desired quality attributes.
Quality Target Product Profile (QTPP)
The QTPP defines the intended quality characteristics of the product.
Examples
Critical Quality Attributes (CQAs)
CQAs directly influence product performance.
Critical Material Attributes (CMAs)
CMAs refer to raw material properties affecting formulation quality. Examples
Critical Process Parameters (CPPs)
CPPs are manufacturing variables influencing product quality. Examples
Quality by Design (QbD)
Quality by Design is a scientific and risk-based approach recommended by regulatory authorities.
Benefits
QbD Workflow
Design of Experiments (DoE)
DoE allows systematic investigation of formulation variables.
Advantages
Box-Behnken Design (BBD)
Box-Behnken Design is widely used for optimization of nanoformulations.
Independent Variables
Dependent Variables
Benefits
Response Surface Methodology (RSM)
RSM is employed to evaluate relationships between variables and responses.
Applications
Table 2: Optimization Parameters
|
Parameter |
Desired Outcome |
|
Particle Size |
<200 nm |
|
PDI |
<0.3 |
|
Zeta Potential |
±30 mV |
|
Entrapment Efficiency |
>80% |
|
Drug Release |
Sustained |
|
Stability |
High |
Characterizations Of Nano-Embedded Losartan Potassium Transdermal Systems
Characterization is an essential step in the development of nano-embedded transdermal systems. It ensures product quality, stability, safety, and therapeutic efficacy.
Particle Size Analysis
Particle size is one of the most critical parameters affecting skin permeation and drug release behavior.
Importance
Method
Dynamic Light Scattering (DLS) is commonly used for particle size determination.
Desired Range
Nanoparticles: 10–200 nm
Nanoemulsions: 20–200 nm
Smaller particles generally provide better permeation through the start um corneum.
Polydispersity Index (PDI) PDI
indicates particle size distribution. Interpretation
An ideal nanoformulation should possess a PDI below 0.3.
|
PDI Value |
Interpretation |
|
<0.1 |
Highly uniform |
|
0.1–0.3 |
Acceptable |
|
>0.3. |
istribution |
Evaluation of Transdermal Patches
Physical Appearance The patch should be:
Thickness Measurement
Folding Endurance
In-Vitro Drug Release Studies
In-vitro drug release studies evaluate drug release behavior under controlled laboratory conditions.
Equipment
Parameters Evaluated
Common Kinetic Models
Stability Studies
Stability testing is conducted according to ICH guidelines.
Storage Conditions
Accelerated Studies
Long-Term Studies
Parameters Monitored
Recent Research Advances
Recent advances in nanotechnology have significantly improved transdermal drug delivery systems.
Nanostructured Lipid Carriers
Provide higher drug loading and improved permeation.
Hybrid Nanoparticles
Combine advantages of polymeric and lipid-based systems.
Microneedle-Assisted Delivery
Creates microchannels that facilitate drug transport.
Stimuli-Responsive Systems
Release drugs in response to:
Artificial Intelligence in Formulation Design
AI-based models are increasingly being used to optimize nanoformulations and predict drug release patterns.
FUTURE PERSPECTIVES
Future research should focus on:
The integration of nanotechnology with digital health devices may revolutionize antihypertensive therapy.
CONCLUSION
Losartan potassium remains an important antihypertensive drug; however, its oral administration is associated with limitations such as first-pass metabolism and reduced bioavailability. Nano-embedded transdermal therapeutic systems offer a promising alternative approach by enhancing skin permeation, improving drug stability, providing controlled drug release, and increasing patient compliance. Nanocarriers including polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and liposomes have demonstrated significant potential in improving transdermal delivery of losartan potassium. Optimization strategies such as Quality by Design, Design of Experiments, and Response Surface Methodology facilitate the development of robust formulations. Comprehensive characterization techniques ensure quality, safety, and efficacy. Future advances in nanotechnology, smart delivery systems, and personalized medicine are expected to further expand the clinical utility of nano-embedded transdermal therapeutic systems for hypertension management.
REFERENCES
Kajal Maurya, Shashank Tiwari*, Sadhna Singh, Design, Optimization, and Characterization of Nano Embedded Losartan Potassium Transdermal Therapeutic System, Int. J. Med. Pharm. Sci., 2026, 2 (7), 113-122. https://doi.org/10.5281/zenodo.21238007
10.5281/zenodo.21238007